Tag Archives: acor

Acorda, Allergan Make Surprise Deal On Ampyra Patent

Biotech Acorda Therapeutics (ACOR) said Monday that it had reached a settlement with Actavis, the generic-drug arm of Allergan (AGN), agreeing that Actavis’ generic version of Acorda’s drug Ampyra won’t come out until 2027. Acorda stock rose sharply while Allergan’s fell. The news, which was revealed only through a terse SEC filing, came as a big surprise to Wall Street. Most had expected the generic version of Acorda’s multiple-sclerosis drug to

Acorda Stock Jumps After Bass Patent Petitions Nixed

Biotech stock Acorda Therapeutics (ACOR) soared 18% in early trading in the stock market today, a day after a court dismissed a patent challenge in a move that could have wider implications in the drug space. Late Monday, Acorda announced that the Patent Trials and Appeal Board (PTAB) had declined to institute the inter partes review (IPR) requested on two patents related to multiple-sclerosis drug Ampyra. The challenger was Kyle Bass, principal

Civitas Buyout Shores Up Acorda’s Wall Street Cred

It’s been an interesting year for drugmaker Acorda Therapeutics. The neurology specialist has been working to diversify from Ampyra, a drug that helps multiple sclerosis patients walk and which provided 90% of Acorda’s (ACOR) revenue in the most recent quarter. Ampyra, launched in 2010, has proved a success in its narrow specialty, with 12-month sales running upward of $300 million. But the drug’s growth has been slowing, and it is already facing